- Meeting abstract
- Open Access
HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
Breast Cancer Research volume 2, Article number: P3.07 (2000)
Activation of the HER-2 proto-oncogene and inactivation of the TP53 tumour-suppressor gene belong to the most common genetic changes in human breast carcinomas. Both appear to be of prognostic significance, at least in patients with node-positive disease. The relevance of these changes in node-negative disease, however, still remains uncertain. Moreover, the relationship between HER-2 and TP53 status remains to be fully clarified.
HER-2 and TP53 status were determined in 261 breast carcinomas collected from Norwegian breast cancer patients diagnosed between 1984 and 1994. HER-2 status was determined using immunohistochemistry. A subset of the tumours was also examined with regard to gene amplification using the Southern blot technique. A significant association was found between the presence of gene amplification and positive HER-2 immunostaining in the tumour. The tumours were also examined for TP53 alterations using CDGE (constant denaturant gel electrophoresis) and immunohistochemistry. A significant association was found between the presence of HER-2 activation and TP53 inactivation in the tumour. Survival analyses will be presented.
About this article
Cite this article
Andersen, T., Skovlund, E., Bukholm, I. et al. HER-2 activation and TP53 inactivation as predictors of survival in breast cancer. Breast Cancer Res 2, P3.07 (2000) doi:10.1186/bcr158
- Breast Cancer
- Breast Carcinoma
- Gene Amplification
- Human Breast Carcinoma
- TP53 Status